EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy

被引：0
|
作者：
Kim, Minhye [1 ]
Na, Ji Min [1 ]
Lee, Gyeong-Won [2 ]
Lee, Seung Jun [3 ]
Kim, Jong Duk [4 ]
Yang, Jung Wook [5 ]
机构：
[1] Gyeonsang Natl Univ Hosp, Dept Pathol, Jinju, South Korea
[2] Gyeongsang Natl Univ, Div Hematol Oncol, Dept Internal Med, Gyeonsang Natl Univ Hosp,Coll Med, Jinju, South Korea
[3] Gyeongsang Natl Univ, Coll Med, Gyeonsang Natl Univ Hosp, Div Pulmonol & Allergy,Dept Internal Med, Jinju, South Korea
[4] Gyeonsang Natl Univ Hosp, Dept Cardiothorac Surg, Jinju, South Korea
[5] Gyeongsang Natl Univ, Coll Med, Gyeonsang Natl Univ Hosp, Dept Pathol, 79 Gangnam Ro, Jinju 52727, South Korea
来源：
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE | 2021年 / 55卷 / 01期
关键词：
IMPACT;
D O I：
10.4132/jptm.2020.11.02
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：79 / 82
页数：4
相关论文
共 50 条
  • [31] Effects of vandetanib on lung adenocarcinoma cells harboring an EGFR T790M mutation in vivo
    Ichihara, Eiki
    Ohashi, Kadoaki
    Takigawa, Nagio
    Osawa, Masahiro
    Takeda, Hiromasa
    Ochi, Nobuaki
    Harada, Daijiro
    Yasugi, Masayuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2009, 69
  • [32] Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation
    Santoni-Rugiu, Eric
    Grauslund, Morten
    Melchior, Linea C.
    Costa, Junia C.
    Sorensen, Jens B.
    Urbanska, Edyta M.
    LUNG CANCER, 2017, 113 : 14 - 17
  • [33] Emergence of CCDC6-RET Fusion with Maintained EGFR T790M Mutation After Resistance to Osimertinib in NSCLC: A Case Report
    Guo, Y.
    Guo, R.
    Cheng, H.
    Wang, H.
    Lou, F.
    Cao, S.
    Guo, W.
    Song, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S846 - S846
  • [34] EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib
    Ma, Lei
    Chen, Rui
    Wang, Fang
    Ma, Li-Li
    Yuan, Ming-Ming
    Chen, Rong-Rong
    Liu, Jiang
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (09)
  • [35] Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
    Zhang, Shirong
    Zheng, Xiaoliang
    Huang, Haixiu
    Wu, Kan
    Wang, Bing
    Chen, Xufeng
    Ma, Shenglin
    ONCOTARGET, 2015, 6 (08) : 5832 - 5845
  • [36] T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report
    Han, Jialong
    Wang, Ya
    Zhong, Lili
    Zhou, Huijie
    Yu, Min
    Li, Yanying
    Lu, You
    Wang, Yan
    Zhu, Jiang
    PRECISION CLINICAL MEDICINE, 2018, 1 (03) : 129 - 133
  • [37] Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer
    Iijima, Yuki
    Hirotsu, Yosuke
    Mochizuki, Hitoshi
    Ikmemiya, Kenji
    Oyama, Toshio
    Uchida, Yoshinori
    Kobayashi, Yoichi
    Tsutsui, Toshiharu
    Kakizaki, Yumiko
    Miyashita, Yoshihiro
    Omata, Masao
    CLINICAL LUNG CANCER, 2018, 19 (06) : E843 - E847
  • [38] Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study
    Kaburagi, Takayuki
    Kiyoshima, Moriyuki
    Nawa, Takeshi
    Ichimura, Hideo
    Saito, Takefumi
    Hayashihara, Kenji
    Yamada, Hideyasu
    Satoh, Hiroaki
    Endo, Takeo
    Inage, Yoshihisa
    Saito, Kazuhito
    Inagaki, Masaharu
    Hizawa, Nobuyuki
    Sato, Yukio
    Ishikawa, Hiroichi
    Sakai, Mitsuaki
    Kamiyama, Koichi
    Kikuchi, Norihiro
    Nakamura, Hiroyuki
    Furukawa, Kinya
    Kodama, Takahide
    Yamashita, Takaaki
    Nomura, Akihiro
    Yoshida, Susumu
    ANTICANCER RESEARCH, 2018, 38 (05) : 3145 - 3150
  • [39] Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)
    Solomon, B.
    Mersiades, A.
    Brown, C.
    Dawson, S.
    Wong, S.
    Tan, L.
    Yip, S.
    Cheung, Y.
    Jurkovic, H.
    Walker, M.
    Kao, S.
    Lee, C. K.
    Newnham, G.
    O'Byrne, K.
    Parakh, S.
    Jasas, K.
    Bray, V.
    Stockler, M.
    John, T.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S615 - S616
  • [40] T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
    Kusaba, Yusaku
    Takeda, Yuichiro
    Abe, Sakurako
    Tsukada, Akinari
    Naka, Go
    MEDICINE, 2022, 101 (32) : E29682
12345